Journal
BLOOD
Volume 120, Issue 14, Pages 2918-2924Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-03-417758
Keywords
-
Categories
Funding
- Public Health Service from National Cancer Institute (NCI) [U24-CA76518]
- Public Health Service from National Heart, Lung, and Blood Institute (NHLBI) [U24-CA76518]
- Public Health Service from National Institute of Allergy and Infectious Diseases (NIAID) [U24-CA76518]
- NHLBI [5U01HL069294]
- NCI [5U01HL069294]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- Allos Inc
- Amgen Inc
- Angioblast
- Ariad
- Be the Match Foundation
- Blue Cross and Blue Shield Association
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix GmbH
- Children's Leukemia Research Association
- Fresenius-Biotech North America Inc
- Gamida Cell Teva Joint Venture Ltd
- Genentech Inc
- Genzyme Corporation
- GlaxoSmithKline
- HistoGenetics Inc
- Kiadis Pharma
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck Co Inc
- Millennium: The Takeda Oncology Co
- Milliman USA Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Optum Healthcare Solutions Inc
- Osiris Therapeutics Inc
- Otsuka America Pharmaceutical Inc
- RemedyMD
- Sanofi
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- Soligenix Inc
- Stem-Cyte, A Global Cord Blood Therapeutics Co
- Stemsoft Software Inc
- Swedish Orphan Biovitrum
- Tarix Pharmaceuticals
- Teva Neuroscience Inc
- THERAKOS Inc
- Wellpoint Inc
Ask authors/readers for more resources
The importance of human leukocyte antigen (HLA) matching in unrelated donor transplantation for nonmalignant diseases (NMD) has yet to be defined. We analyzed data from 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007 for treatment of NMD. Transplantation from a donor mismatched at the HLA-A, -B, -C, or -DRB1, but not -DQB1 or -DPB1, loci was associated with higher mortality in multivariate analyses (P = .002). The hazard ratio for mortality for single (7/8) and double mismatched (6/8) transplants was 1.29 (0.97-1.72; P = .079) and 1.82 (1.30-2.55; P = .0004), respectively, compared with 8/8 matched transplants. HLA mismatches were not associated with acute or chronic GVHD, but were strongly associated with graft failure. After adjustment for other factors, the odds ratio for graft failure for 7/8 and 6/8 (allele and/or antigen) matched pairs compared with 8/8 matched transplants was 2.81 (1.74-4.54; P < .0001) and 2.22 (1.26-3.97; P = .006), respectively. Patients with NMD should receive transplants from allele matched (8/8) donors if possible. Unlike the case with malignancies, HLA mismatching in NMD is associated with graft failure rather than GVHD. (Blood. 2012; 120(14): 2918-2924)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available